OM:PLED

Stock Analysis Report

Executive Summary

PledPharma AB, a pharmaceutical company, develops pharmaceuticals for the treatment of debilitating and life-threatening medical conditions.


Snowflake Analysis

Exceptional growth potential with excellent balance sheet.

Share Price & News

How has PledPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PLED's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-37.4%

PLED

4.6%

SE Biotechs

4.0%

SE Market


1 Year Return

-77.8%

PLED

-25.6%

SE Biotechs

-6.4%

SE Market

Return vs Industry: PLED underperformed the Swedish Biotechs industry which returned -26.7% over the past year.

Return vs Market: PLED underperformed the Swedish Market which returned -9.8% over the past year.


Shareholder returns

PLEDIndustryMarket
7 Day-37.4%4.6%4.0%
30 Day-33.6%0.7%-8.3%
90 Day-78.1%-4.7%-17.8%
1 Year-77.8%-77.8%-24.9%-25.6%-4.4%-6.4%
3 Year-65.2%-65.2%11.7%6.9%6.8%-8.3%
5 Year-85.8%-85.8%50.5%37.1%13.7%-9.9%

Price Volatility Vs. Market

How volatile is PledPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PledPharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PLED (SEK4.38) is trading below our estimate of fair value (SEK236.28)

Significantly Below Fair Value: PLED is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PLED is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PLED is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PLED's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PLED is good value based on its PB Ratio (1x) compared to the SE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is PledPharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

95.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PLED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: PLED is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PLED's is expected to become profitable in the next 3 years.

Revenue vs Market: PLED's revenue (56.8% per year) is forecast to grow faster than the Swedish market (4.2% per year).

High Growth Revenue: PLED's revenue (56.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PLED's Return on Equity is forecast to be very high in 3 years time (51%).


Next Steps

Past Performance

How has PledPharma performed over the past 5 years?

-10.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PLED is currently unprofitable.

Growing Profit Margin: PLED is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PLED is unprofitable, and losses have increased over the past 5 years at a rate of -10.4% per year.

Accelerating Growth: Unable to compare PLED's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PLED is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.6%).


Return on Equity

High ROE: PLED has a negative Return on Equity (-25.08%), as it is currently unprofitable.


Next Steps

Financial Health

How is PledPharma's financial position?


Financial Position Analysis

Short Term Liabilities: PLED's short term assets (SEK270.0M) exceed its short term liabilities (SEK25.1M).

Long Term Liabilities: PLED's short term assets (SEK270.0M) exceed its long term liabilities (SEK116.0K).


Debt to Equity History and Analysis

Debt Level: PLED is debt free.

Reducing Debt: PLED has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PLED has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PLED has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is PledPharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PLED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PLED's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PLED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PLED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PLED's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.3yrs

Average management tenure


CEO

Nicklas Westerholm (43yo)

2.83s

Tenure

kr2,936,000

Compensation

Mr. Nicklas Westerholm has been the Chief Executive Officer of PledPharma AB since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca Group since 1995 in several global roles and different b ...


CEO Compensation Analysis

Compensation vs Market: Nicklas's total compensation ($USD289.98K) is above average for companies of similar size in the Swedish market ($USD207.01K).

Compensation vs Earnings: Nicklas's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Nicklas Westerholm
Chief Executive Officer2.83yrskr2.94m0.030% SEK70.1k
Torsten Almén
14.25yrsno datano data
Ingemar Lundström
14.25yrsno datano data
Louis Ignarro
14.25yrsno datano data
Heidi Brurok
14.25yrsno datano data
Rob Towart
14.25yrsno datano data
Yilmaz Mahshid
Chief Financial Officer2.33yrsno data0.030% SEK70.1k
Jacques Näsström
Chief Scientific Officerno datakr655.00k0.15% SEK352.4k
Stefan Carlsson
Chief Medical Officer2.42yrsno datano data

14.3yrs

Average Tenure

59.5yo

Average Age

Experienced Management: PLED's management team is seasoned and experienced (14.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Håkan Åström
Chairman9.25yrskr600.00k0.94% SEK2.2m
Sten Nilsson
Director7.25yrskr165.00k0.0021% SEK4.8k
Marie Tragardh
Director3yrskr165.00kno data
Bengt Glimelius
Member of Scientific Advisory Board2.67yrsno datano data
Gunilla Osswald
Director3.25yrskr165.00kno data
Elisabeth Svanberg
Director3.25yrskr165.00kno data
Guido Cavaletti
Member of Scientific Advisory Board2.67yrsno datano data
David Cella
Member of Scientific Advisory Board2.67yrsno datano data
Rolf Karlsten
Member of Scientific Advisory Board2.67yrsno datano data
Laura James
Member of Scientific Advisory Board1.83yrsno datano data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Board: PLED's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PLED insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.1%.


Top Shareholders

Company Information

PledPharma AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PledPharma AB
  • Ticker: PLED
  • Exchange: OM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr234.476m
  • Shares outstanding: 53.53m
  • Website: https://pledpharma.com

Number of Employees


Location

  • PledPharma AB
  • Grev Turegatan 11 C
  • Stockholm
  • Stockholm County
  • 114 46
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PLEDOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKApr 2011
P0FBST (Boerse-Stuttgart)YesShare CapitalDEEURApr 2011
P0FDB (Deutsche Boerse AG)YesShare CapitalDEEURApr 2011

Biography

PledPharma AB, a pharmaceutical company, develops pharmaceuticals for the treatment of debilitating and life-threatening medical conditions. It is developing PledOx, which is in Phase III clinical trial to protect patients with colorectal cancer against Cellgiftsinducerad peripheral neuropathy, a disabling effect of chemotherapy treatment; and Aladote to reduce acute liver failure damage caused by acetaminophen/paracetamol poisoning. The company was founded in 2006 and is headquartered in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 22:42
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.